Sign In
8 Jan 2016 07:00
8 January 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Directorate Change
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that Non-Executive Chairman David Evans, aged 55, has resigned his position on the Board in line with his personal commitment to reduce the number of Non-Executive Chairman roles currently undertaken.
David remains a keen supporter and shareholder of Venn and will work with the Board to find a suitable replacement and to facilitate a smooth handover to his successor; a process which the Company hopes to conclude by April 2016. In the interim period Tony Richardson will act as executive Chairman.
Commenting, David Evans, said:
"I am pleased to have contributed to Venn's growth through its Admission to the AIM market in 2012 and successful execution of a pan-European acquisition strategy. The business is now clearly demonstrating that it is well positioned to bid for and secure larger scale projects and to offer clients a much wider range of capabilities across numerous geographies. Shareholders in Venn, and I include myself in this, will be delighted to see a business with a growing client base, a strong forward order book and the opportunity to secure high quality repeat business. I believe now is a good time to seek a successor who can take on the Chairman's role as Venn enters a new phase of growth."
Venn CEO, Tony Richardson said:
"On behalf of the Board I would like to thank David for his contribution over the last 4 years. We have welcomed his support and advice as we've grown the business and appreciate that his experience has been invaluable for the successful execution of our strategy."
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | |
Jonathan Hartshorn, Chief Financial Officer | Tel: +353 153 93 269 | |
Orla McGuinness, Marketing Manager | Tel: +353 153 93 269 | |
Zeus Capital (Nominated Adviser and Joint Broker) | ||
Andrew Jones / Phil Walker | ||
Dominic Wilson / Alex Davis | Tel :+44(0)20 3829 5000 | |
| ||
Hybridan LLP (Joint-Broker) |
| |
Claire Louise Noyce | Tel: +44(0)20 3764 2341 | |
| ||
Walbrook PR Ltd | Tel: 020 7933 8787 or venn@walbrookpr.com | |
Lianne Cawthorne | Mob: 07584 391 303 | |
About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
For more information about the Company, please visit: www.vennlifesciences.com
Follow the stocks
